Nataliya Mar

10PUBLICATIONS
33CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersMolecular targetsNeurology and neuromuscular diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jan 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.

Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes

|Jul 04, 2023
Drug extravasation with Enfortumab vedotin.

Christopher Ryan Grant, Dimitri de Kouchkovsky, Arash Rezazadeh Kalebasty

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

|Jan 19, 2022
Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.

Armon Azizi, Roozbeh Houshyar, Nataliya Mar

Pageof 2